| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 148261 USD | -466362 USD | -699686 USD | -409545 USD | -249838 USD | -42260 USD | 608312 USD | 1.26 M USD | 841216 USD | 2.90 M USD | 3.35 M USD | 4.57 M USD |
| Depreciation & Amortization | 1.50 M USD | 2.62 M USD | 2.75 M USD | 2.70 M USD | 3.09 M USD | 2.68 M USD | 2.93 M USD | 3.26 M USD | 3.29 M USD | 3.08 M USD | 3.60 M USD | 1.79 M USD |
| Stock-Based Compensation | — | — | — | — | — | — | — | — | — | — | — | — |
| Capital Expenditures | 59324 USD | 38411 USD | 11517 USD | 401964 USD | 438055 USD | 867307 USD | 136003 USD | 51145 USD | 136479 USD | -193404 USD | 685302 USD | -5.13 M USD |
| Cash Flow from Investing | -137251 USD | -291718 USD | -11517 USD | -401964 USD | -438055 USD | -867307 USD | -136003 USD | -51145 USD | -136479 USD | -193404 USD | -1.90 M USD | -5.84 M USD |
| Cash Flow from Financing | -294027 USD | 27353 USD | 73145 USD | -1.77 M USD | 4.60 M USD | 624177 USD | -1.73 M USD | -1.98 M USD | -1.48 M USD | -6.02 M USD | 0 USD | 605002 USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 88937 USD | -504773 USD | -711203 USD | -811509 USD | -687893 USD | -909567 USD | 472309 USD | 1.21 M USD | 704737 USD | 3.09 M USD | 2.66 M USD | 9.70 M USD |
China Pharma Holdings Inc. is a provider of pharmaceutical products known for its focus on the development, production, and marketing of generic and specialty drugs. The company operates primarily within the healthcare and pharmaceutical sectors, contributing significantly to the medical supply chain. Its portfolio includes a diverse range of products that address common health needs such as antibiotics, cardiovascular medications, and pain relief, positioning it as a crucial player in providing affordable healthcare solutions. China Pharma Holdings Inc. is particularly impactful in the Chinese market, leveraging extensive research and development capabilities to introduce effective treatment options. The company's operations are not just limited to drug manufacturing; they also involve significant efforts in distribution to ensure widespread accessibility of their medicines. With an aging global population and increasing demand for cost-effective healthcare solutions, China Pharma plays a vital role in meeting these needs, enhancing the treatment landscape not only in China but also in other countries. By adhering to stringent quality standards and regulatory compliances, China Pharma Holdings Inc. reinforces its commitment to improving health outcomes across its operational markets.